Update from RBS Morgans today
"Alchemia (ACL, Buy, Price Target 89c) - GSK numbers overnight show continuing decline in Arixtra sales in the US recorded $US25 million down 32 per cent of previous period and down 64 per cent on pcp. This is
positive for Alchemia with its marketing partner Dr Reddy's gaining solid market share estimated at least 30 per cent in the retail pharmacy channel."
Reuters.
gsk arixtra sales, page-6
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable